Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Xavier Thomas, Mohamed Elhamri, Alexandre Deloire & Maël Heiblig. (2022) Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. Expert Opinion on Emerging Drugs 27:2, pages 169-185.
Read now
Read now
Sergey E Sedykh, Victor V Prinz, Valentina N Buneva & Georgy A Nevinsky. (2018) Bispecific antibodies: design, therapy, perspectives. Drug Design, Development and Therapy 12, pages 195-208.
Read now
Read now
Troy A McEachron, Timothy J Triche, Laurie Sorenson, David M Parham & John D Carpten. (2018) Profiling targetable immune checkpoints in osteosarcoma. OncoImmunology 7:12.
Read now
Read now
Seandean Lykke Harwood, Ana Alvarez-Cienfuegos, Natalia Nuñez-Prado, Marta Compte, Sara Hernández-Pérez, Nekane Merino, Jaume Bonet, Rocio Navarro, Paul M. P. Van Bergen en Henegouwen, Simon Lykkemark, Kasper Mikkelsen, Kasper Mølgaard, Frederic Jabs, Laura Sanz, Francisco J. Blanco, Pedro Roda-Navarro & Luis Alvarez-Vallina. (2018) ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. OncoImmunology 7:1.
Read now
Read now
Ulrich Brinkmann & Roland E. Kontermann. (2017) The making of bispecific antibodies. mAbs 9:2, pages 182-212.
Read now
Read now
Archana Thakur & Lawrence G. Lum. (2016) “NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results. Expert Opinion on Biological Therapy 16:5, pages 675-688.
Read now
Read now
Mahiuddin Ahmed, Ming Cheng, Irene Y Cheung & Nai-Kong V Cheung. (2015) Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. OncoImmunology 4:4.
Read now
Read now
Giuseppe Di Caro, Giovanni Francesco Castino, Francesca Bergomas, Nina Cortese, Maurizio Chiriva-Internati, Fabio Grizzi & Federica Marchesi. (2014) Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. Expert Review of Anticancer Therapy 14:10, pages 1219-1228.
Read now
Read now
Articles from other publishers (21)
Rajeev Pasupuleti, Francesca Rosato, Dajana Kolanovic, Olga N. Makshakova, Winfried Römer & Birgit Wiltschi. (2023) Genetic code expansion in E. coli enables production of a functional ‘ready-to-click’ T cell receptor-specific scFv. New Biotechnology 76, pages 127-137.
Crossref
Crossref
Joshua F. Meckler, Daniel J. Levis, Daniel P. Vang & Joseph M. Tuscano. (2023) A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model. Cancer Immunology, Immunotherapy 72:9, pages 2939-2948.
Crossref
Crossref
Fadi Haddad, Amer M. Zeidan & Naval Daver. (2022) Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. The Cancer Journal 28:1, pages 43-50.
Crossref
Crossref
Rebecca Epperly, Stephen Gottschalk & M. Paulina Velasquez. 2022. Gene and Cellular Immunotherapy for Cancer. Gene and Cellular Immunotherapy for Cancer
329
351
.
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian & Antonio Curti. (2021) Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology 11.
Crossref
Crossref
Seil Jang, Jaeho Song, NaYoung Kim, Jeonghyeon Bak, Keehoon Jung, Young Woo Park, Bum-Chan Park & Ho Min Kim. (2021) Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy. Biomaterials 271, pages 120760.
Crossref
Crossref
Fadi Haddad & Naval Daver. 2021. Immunotherapy. Immunotherapy
273
295
.
Siwei Nie, Zhuozhi Wang, Maria Moscoso-Castro, Paul D'Souza, Can Lei, Jianqing Xu & Jijie Gu. (2020) Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Therapeutics 3:1, pages 18-62.
Crossref
Crossref
S. E. Sedykh & G. A. Nevinsky. (2019) Producing and prospects for the use of bispecific antibodies for the treatment of cancer. Advances in molecular oncology 5:4, pages 30-40.
Crossref
Crossref
Bing Zhou, Longfa Xu, Rui Zhu, Jixian Tang, Yangtao Wu, Ruopeng Su, Zhichao Yin, Dongxiao Liu, Yichao Jiang, Can Wen, Min You, Linlin Dai, Yu Lin, Yuanzhi Chen, Haijie Yang, Zhiqiang An, Changfa Fan, Tong Cheng, Wenxin Luo & Ningshao Xia. (2019) A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antiviral Research 161, pages 28-35.
Crossref
Crossref
Lilach Vaks, Dana Litvak-Greenfeld, Stav Dror, Galia Matatov, Limor Nahary, Shiran Shapira, Rahely Hakim, Iris Alroy & Itai Benhar. (2018) Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds. Antibodies 7:3, pages 27.
Crossref
Crossref
David M. Goldenberg, Rhona Stein & Robert M. Sharkey. (2018) The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 9:48, pages 28989-29006.
Crossref
Crossref
Markus Kieler, Matthias Unseld, Daniela Bianconi & Gerald Prager. (2018) Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. Pancreas 47:2, pages 142-157.
Crossref
Crossref
Z. Wu & N.V. Cheung. (2018) T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics. Pharmacology & Therapeutics 182, pages 161-175.
Crossref
Crossref
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li & Zhong Wang. (2018) Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLOS ONE 13:1, pages e0191024.
Crossref
Crossref
Chien-Hsing Chang, Yang Wang, Rongxiu Li, Diane L. Rossi, Donglin Liu, Edmund A. Rossi, Thomas M. Cardillo & David M. Goldenberg. (2017) Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. Cancer Research 77:19, pages 5384-5394.
Crossref
Crossref
Hong Wu, Li Yao, Lin Chou, Jin‑Hua Yang, Yun‑Xiu Zhang, Xiao‑Li Li & Bo‑Er Shan. (2016) Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody. Molecular Medicine Reports.
Crossref
Crossref
Joanie Del Bano, Patrick Chames, Daniel Baty & Brigitte Kerfelec. (2015) Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. Antibodies 5:1, pages 1.
Crossref
Crossref
Natalia Nuñez-Prado, Marta Compte, Seandean Harwood, Ana Álvarez-Méndez, Simon Lykkemark, Laura Sanz & Luis Álvarez-Vallina. (2015) The coming of age of engineered multivalent antibodies. Drug Discovery Today 20:5, pages 588-594.
Crossref
Crossref
Alison J. Smith. (2015) New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics. SLAS Discovery 20:4, pages 437-453.
Crossref
Crossref
Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang & David M. Goldenberg. (2014) Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α. Molecular Cancer Therapeutics 13:10, pages 2341-2351.
Crossref
Crossref